AC Immune SAのボラティリティ
AC Immune SAのボラティリティは何ですか。
AC Immune SAのボラティリティは6.32%です。
ボラティリティの定義は何ですか。
ボラティリティまたは平均真の範囲パーセント（ATRP14）は、終値のパーセンテージとして表されるATRです。
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
NASDAQのセクタHealth Careにおけるボラティリティの企業と比べるAC Immune SA
AC Immune SAは何をしますか。
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
AC Immune SAと類似のボラティリティ
- Supernova Partners Acquisitionのボラティリティは6.31%です。
- Voleo Trading Systemsのボラティリティは6.31%です。
- Marinus Pharmaceuticals Incのボラティリティは6.31%です。
- Shiseido Coのボラティリティは6.31%です。
- Ester Industriesのボラティリティは6.31%です。
- Winsome Textile Industriesのボラティリティは6.31%です。
- AC Immune SAのボラティリティは6.32%です。
- Adocia SAのボラティリティは6.33%です。
- Gpo Plus Incのボラティリティは6.33%です。
- Saboo Sodium Chloroのボラティリティは6.33%です。
- Tortoise Acquisition IIのボラティリティは6.33%です。
- Prospector Metals Corpのボラティリティは6.33%です。
- Stoke Therapeuticsのボラティリティは6.33%です。